The Phase III IMforte study shows that adding lurbinectedin to Tecentriq for ES-SCLC first-line maintenance reduced disease ...

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a ...

Satri-cel, a CLDN18.2-targeted CAR T-cell therapy, nearly doubles progression-free survival in patients with previously ...

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.